La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Bionano Genomics Bilan de santé

Santé financière contrôle des critères 6/6

Bionano Genomics possède un total de capitaux propres de $80.3M et une dette totale de $19.4M, ce qui porte son ratio d'endettement à 24.1%. Son actif total et son passif total sont $129.4M et de $49.0M.

Informations clés

24.1%

Ratio d'endettement

US$19.36m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$18.94m
Fonds propres	US$80.34m
Total du passif	US$49.03m
Total des actifs	US$129.36m

Mises à jour récentes de la santé financière

Recent updates

Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Earnings Pushing Shares 31% Lower

May 09

Bionano Genomics, Inc. (NASDAQ:BNGO) Analysts Just Trimmed Their Revenue Forecasts By 9.0%

Mar 14

Bionano Genomics: Little Clinical Utility And A Whole Lot Of Burn

Oct 18

Bionano stock dips amid launch of Bionano Laboratories for optical genome mapping tests

Sep 23

Bionano jumps 36% as publication highlights optical genome mapping

Aug 11

Bionano stock down ~8% after hours; co reports Q2 revenue beat, wider loss

Aug 04

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de BNGO ( $60.6M ) dépassent ses passifs à court terme ( $37.2M ).

Passif à long terme: Les actifs à court terme de BNGO ( $60.6M ) dépassent ses passifs à long terme ( $11.9M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de BNGO ( 0.5% ) est considéré comme satisfaisant.

Réduire la dette: BNGO avait des capitaux propres négatifs il y a 5 ans, mais ils sont désormais positifs et se sont donc améliorés.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: BNGO dispose d'une piste de trésorerie suffisante pour 2 mois sur la base du dernier flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

Prévisions de trésorerie: BNGO devrait disposer d'une marge de trésorerie suffisante pour 2 mois sur la base des estimations de flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

Bionano Genomics Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Bionano Genomics Receives Non-Compliance Letter from the Nasdaq Stock Market

Bionano Genomics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Bionano Genomics Receives Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with Minimum Bid Price Requirement

Recent updates

Consensus EPS estimates upgraded to US$1.30 loss

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Bionano Genomics, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2024

Bionano Genomics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Bionano Genomics, Inc. Announces Publication of First Multi-Site Study to Analyze the Utility of OGM in Multiple Myeloma

Bionano Genomics Receives Non-Compliance Letter from the Nasdaq Stock Market

Bionano Genomics, Inc. has completed a Follow-on Equity Offering in the amount of $9.994188 million.

Bionano Genomics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000001 million.

Bionano Genomics, Inc. Provides Revenue Guidance for the Second Quarter of 2024 and Reiterated Revenue Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bionano Genomics, Inc., Annual General Meeting, Jun 18, 2024

Bionano Genomics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000002 million.

Bionano Announces Publication Showing That Ogm Identifies Genetic Aberrations in Sarcoma Samples That May Lead to Improved Diagnosis But Were Missed by Classical Cytogenetics

Bionano Genomics, Inc. Announces Nine Poster Presentations and Introduces New High Throughput Stratys System at American Association for Cancer Research Annual Meeting

Bionano Genomics, Inc. Announces Publication of Breast Cancer Study Showing the Number of SVs Detected with OGM May be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Consensus revenue estimates decrease by 16%, EPS upgraded

New major risk - Shareholder dilution

Bionano Genomics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Full year 2023 earnings released: US$6.81 loss per share (vs US$4.59 loss in FY 2022)

Bionano Genomics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Bionano Genomics, Inc. announced that it has received $35 million in funding

Bionano Genomics, Inc. Announces Publication of A Study That Applied Ogm to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer

Consensus EPS estimates fall by 20%

Bionano Announces Full Commercial Release of the Stratys™? System for High Throughput Optical Genome Mapping

Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care in Genetic Disease Testing

Bionano Genomics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Bionano Announces Significant Upgrades to Its Bionano Solve Pipeline and Its Via™ Software for Ogm Data Analysis in Constitution Genetic Disease Research

Price target increased by 10% to US$12.33

Bionano Genomics, Inc. Reports Goodwill Impairment for the Three Months Ended September 30, 2023

Third quarter 2023 earnings: Revenues exceed analyst expectations

Bionano Genomics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Bionano Genomics, Inc. announced that it expects to receive $35 million in funding

New minor risk - Market cap size

Bionano Genomics, Inc. Announces the Publication of Study Detailing the Challenges Associated with the Detection and Interpretation of Causal Variants in Mendelian Disease

Bionano Genomics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Bionano Genomics, Inc. Announces Executive Changes

Price target decreased by 17% to US$35.40

Bionano Genomics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Bionano Genomics, Inc. Announces the Stratys System for OGM and VIA™? Software for Hematologic Malignancies

Bionano Genomics, Inc.(NasdaqCM:BNGO) dropped from Russell Small Cap Comp Value Index

Bionano Genomics, Inc. Announces Peer-Reviewed Publication on the Utility of Combining Ogm and A 523-Gene Ngs Panel for Standard Evaluation of Myeloid Cancers

Bionano Announces Commercial Release of New Kits for Its Ionic System Featuring New Chemistry for Nucleic Acid Extraction from Ffpe and Tumor Tissue

Bionano Genomics Receives Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with Minimum Bid Price Requirement

Price target decreased by 14% to US$3.68

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Earnings Pushing Shares 31% Lower

Bionano Genomics, Inc. to Report Q1, 2023 Results on May 09, 2023

Bionano Genomics, Inc. (NASDAQ:BNGO) Analysts Just Trimmed Their Revenue Forecasts By 9.0%

Full year 2022 earnings: EPS misses analyst expectations

Bionano Genomics, Inc. Launches Next-Generation Versions of Its Reagent Kits and Chip Consumable, Along with Updates to Its Instrument Control and Bionano Access Software for the Optical Genome Mapping Workflow

Bionano Genomics, Inc. Announces Publication of Interim Readout from Clinical Trial Run by Consortium Analyzing Optical Genome Mapping as Potential Standard of Care for Prenatal Testing

Bionano Genomics, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Price target decreased to US$7.38

Bionano Genomics, Inc. Announces Publication of Study Utilizing Optical Genome Mapping

Bionano Genomics, Inc. Announces Resignation of Richard Shippy as Chief Business Officer

Bionano Genomics, Inc. Appoints Donna Polizio as Global Head of Market Access

Bionano Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.074 loss in 3Q 2021)

Bionano Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Bionano Genomics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Hamilton and Bionano Genomics, Inc. Announce Commercial Availability of World's First Ultra High Molecular Weight DNA Extraction Automation Solution for OGM

Bionano Genomics: Little Clinical Utility And A Whole Lot Of Burn

Bionano Genomics Announces Publication of Study from Sorbonne Université Showing That WGS Identified Only 63% of Structural Variations That OGM Detected in Liver Cancer

Bionano Genomics Announces Launch of CLIA-Certified Bionano Laboratories

Bionano stock dips amid launch of Bionano Laboratories for optical genome mapping tests

Bionano Genomics, Inc. Announces Publication of Study Using OGM for Detection of Balanced Chromosomal Rearrangements Found in Recurrent Pregnancy Loss

Bionano Genomics Announces Publication of Study Demonstrating Utility of OGM as Part of Comprehensive Workflow for Quality Evaluation of Human Induced Pluripotent Stem Cells

Bionano Genomics, Inc. Announces the First Publication Using OGM to Analyze Impact of Chromothripsis and TP53 Abnormalities on Chronic Lymphocytic Leukemia (CLL) Patients with High Genomic Complexity

Independent Director exercised options and sold US$65k worth of stock

Bionano Genomics Announces First Publication Using Ogm for Detection of Repeat Expansions in Canvas and Adult-Onset Ataxia

Bionano jumps 36% as publication highlights optical genome mapping

Consensus forecasts updated